Effects of intravitreal injection of conbercept and ranibizumab on macular thickness and complications in elderly patients with diabetes and macular edema
Objective To analyze the effects of intravitreal injection of conbercept and ranibizumab on macular thickness and complications in elderly patients with diabetes and macular edema.Methods A total of 106 elderly patients with diabetes and macular edema admitted in our hospital from January to December 2020 were selected as the research objects and randomly divided into ranibizumab group(53 cases,intravitreal injection of ranibizumab)and conbercept group(53 cases,intravitreal injection of conbercept).The therapeutic effects of the two groups were compared.Results The total effective rate of recovery in the conbercept group was significantly higher than that in the ranibizumab group,and the difference was statistically significant(P<0.05).There were no significant differences in uncorrected visual acuity(UCVA),best corrected visual acuity(BCVA)and macular central retinal thickness between the two groups at 30 d before operation(T0),the second day after the first operation(T1)and the second day after the second operation(T2)(P>0.05);at the second day after the third operation(T3)and 30 d after the third operation(T4),the UCVA and BCVA of the conbercept group were significantly higher than those of the ranibizumab group,the macular central retinal thickness was significantly smaller than that of the ranibizumab group,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences of vascular endothelial growth inhibitory factor(VEGI),pigment epithelium derived factor(PEDF),peak systolic velocity(PSV),end diastolic velocity(EDV)and resistance index(RI)between the two groups(P>0.05);after treatment,the VEGI,PEDF,PSV and EDV in the conbercept group were significantly higher than those in the ranibizumab group,the RI was significantly lower than that in the ranibizumab group,and the differences were statistically significant(P<0.05).The total incidence of complications in the conbercept group was significantly lower than that in the ranibizumab group,and the difference was statistically significant(P<0.05).Conclusion Compared with intravitreal injection of ranibizumab,intravitreal injection of conbercept has better effect in the treatment of elderly patients with diabetes and macular edema.
万方数据
维普
